Health and economic burden of influenza‐associated illness in South Africa, 2013‐2015

Autor:	Meredith McMorrow, Stefano Tempia, Orienka Hellferscee, Cheryl Cohen, Sibongile Walaza, Johanna M. McAnerney, Florette K. Treurnicht, Anne von Gottberg, Athermon Nguweneza, Ebrahim Variava, Ijeoma Edoka, Jocelyn Moyes, Nicole Wolter, Adam L. Cohen, Halima Dawood
Rok vydání:	2019
Předmět:	Pulmonary and Respiratory Medicine Epidemiology Total cost 030231 tropical medicine World health South Africa 03 medical and health sciences Indirect costs Life Expectancy 0302 clinical medicine Cost of Illness Environmental health Absenteeism Influenza Human Societal perspective Humans Medicine 030212 general & internal medicine years of life lost health care economics and organizations Respiratory illness business.industry Vaccination Public Health Environmental and Occupational Health virus diseases Original Articles 3. Good health Hospitalization Infectious Diseases Years of potential life lost Influenza Vaccines economic burden Original Article Seasons influenza business Sentinel Surveillance
Zdroj:	Influenza and Other Respiratory Viruses
ISSN:	1750-2659 1750-2640
Popis:	Background Economic burden estimates are essential to guide policy‐making for influenza vaccination, especially in resource‐limited settings. Methods We estimated the cost, absenteeism, and years of life lost (YLL) of medically and non‐medically attended influenza‐associated mild and severe respiratory, circulatory and non‐respiratory/non‐circulatory illness in South Africa during 2013‐2015 using a modified version of the World Health Organization (WHO) worksheet based tool for estimating the economic burden of seasonal influenza. Additionally, we restricted the analysis to influenza‐associated severe acute respiratory illness (SARI) and influenza‐like illness (ILI; subsets of all‐respiratory illnesses) as suggested in the WHO manual. Results The estimated mean annual cost of influenza‐associated illness was $270.5 million, of which $111.3 million (41%) were government‐incurred costs, 40.7 million (15%) were out‐of‐pocket expenses, and $118.4 million (44%) were indirect costs. The cost of influenza‐associated medically attended mild illness ($107.9 million) was 2.3 times higher than that of severe illness ($47.1 million). Influenza‐associated respiratory illness costs ($251.4 million) accounted for 93% of the total cost. Estimated absenteeism and YLL were 13.2 million days and 304 867 years, respectively. Among patients with influenza‐associated WHO‐defined ILI or SARI, the costs ($95.3 million), absenteeism (4.5 million days), and YLL (65 697) were 35%, 34%, and 21% of the total economic and health burden of influenza. Conclusion The economic burden of influenza‐associated illness was substantial from both a government and a societal perspective. Models that limit estimates to those obtained from patients with WHO‐defined ILI or SARI substantially underestimated the total economic and health burden of influenza‐associated illness.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::673909d01a9cb23c001152f1286bdfb2 https://doi.org/10.1111/irv.12650 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.